metelimumab human monoclonal antibody neutralizes tgf beta chosen development treatment diffuse cutaneous systemic sclerosis also known dropped development favour developed genzyme metelimumab isolated cambridge antibody technology cat using phage display technology cat signed collaborative deal genzyme develop tgf beta cat genzyme revealed phase iii trials metelimumab scleroderma showed antibody safe well tolerated across dose levels although conclusions regarding efficacy compound could initial trials targeted skin condition unsuccessful clinical trial results product dropped favour developed genzyme immune activation dostarlimab ibalizumab monoclonal article stub help wikipedia expanding antineoplastic immunomodulatory drug article stub help wikipedia expanding ithttpsenwikipediaorgwikimetelimumab